The brain has a waste-disposal system that clears away junk proteins that contribute to the development of dementia and ...
Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...
Irish Star on MSN23h
Alzheimer's disease could be stopped in its tracks by new drug with potential to 'prevent progression'This drug has the potential to be more targeted than others currently being studied, and we hope it will result in fewer ...
Cassava Sciences Inc. has agreed to a $40 million settlement over SEC charges related to misleading data for simufilam. The ...
After a series of setbacks for dalzanemdor, some analysts now expect that Sage won’t reach profitability for awhile — and only if its cost structure undergoes significant changes.
Sage Therapeutics does not plan further clinical development of its dalzanemdor drug candidate in Alzheimer's disease following its failure in a mid-stage study.
Worcester Telegram on MSN1d
Frontotemporal dementia: Not as well known as Alzheimer's disease but still deadlyFrontotemporal dementia can be hard to diagnose because while dementia can be part of the illness, it's not a factor in all ...
Sage Therapeutics said on Tuesday it would discontinue the development of its experimental drug for Alzheimer's disease as it ...
Outcomes may improve with disease-modifying drugs and lifestyle change if Alzheimer's could be identified earlier.
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...
As of now it's a fatal disease and to find a cure begins with all of us – How you can take steps to join the Walk to End Alzheimer's.
Saturday marked the 16th year for the Walk to End Alzheimer’s here in Victoria, however, the fight for the disease has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback